0000000000297019
AUTHOR
Liga Kuksa
Use of delamanid for M/XDR-TB treatment under programmatic conditions in Latvia
Introduction. Since 2014 Delamanid (Dlm) was introduced in M/XDR-TB treatment under programmatic conditions. The aim of this study was to analyse experience of Dlm use. Methods. For all MDR-TB cases treatment regimens (Tx) are designed by MDR-TB expert committee. Dlm is prescribed for patients with risk of failure of Tx due to resistance or severe intolerance of key 2 nd line drugs. We analysed clinical and demographic data for all patients who received Dlm during the period of July 2014 to February 2016. Data were collected from patient9s medical records. Results. In total 20 MDR TB patients received Dlm: 3 female and 17 male with median age 46 years, including 2 children (11 and 13 years …
Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia
This test decreased time to treatment initiation by 66%–84%.